In addition, Lucarelli et al. reported that troglitazonepromoted the survival of osteosarcoma cells at concentrations of 5 μM, throughthe activation of the PI3-kinase/Akt survival pathway (see Figure 1) [39].Therefore, the administered dose of PPAR-γ ligands in clinical trials for melanoma therapyneeds to be carefully defined and monitored closely. The gene discussed is AKT1; the disease is melanoma.